Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Two interesting Endpoints articles

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 24, 2023 4:29pm

109 Views

Post# 35304434

RE:Two interesting Endpoints articles

As a result of the US Government's Inflation Reduction Act, US based companies are "decoupling" their Chinese partnerships .. and Chinese companies like CStone are putting up their US assets for sale.

"The FDA’s tough stance against single-country data and repetitive PD-1/L1 studies from China affects CStone as well."

https://www.fiercepharma.com/pharma/pfizer-partner-cstone-explores-sale-us-path-blocked-chinese-competition-heats-bloomberg

The Roche / Blueprint "decoupling" is a further consequence of the above.

<< Previous

Bullboard Posts

Next >>

Bombardier settles New York lawsuit with bond investors